The pairing consists of Eli Lilly's LY-CoV555 (bamlanivimab) and Vir Biotechnology's VIR-7831 and produced a 70% reduction in viral load in patients with mild to moderate COVID-19 at day seven after beginning treatment compared to a placebo. The two monoclonal antibodies bind to different regions of the SARS-CoV-2 spike protein, according to the three firms.

Bamlanivimab has not yet been cleared by the U.S. Food and Drug Administration, although it does have an emergency use authorization (EUA), the three companies said. VIR-7831 has also not yet been cleared by the U.S. Food and Drug Administration, although VIR has submitted an emergency use authorization (EUA) application to the agency.

GSK, Vir file EUA submission for COVID-19 mAb treatment
GlaxoSmithKline (GSK) and Vir Biotechnology filed an emergency use authorization (EUA) application with the U.S. Food and Drug Administration for VIR-7831...

Medicago, GSK start phase III of COVID-19 vaccine trial
Medicago and GlaxoSmithKline (GSK) have started phase III of their adjuvanted COVID-19 vaccine candidate clinical trial.

Vir, GSK prepare to submit anti-COVID-19 mAb EUA
Vir Biotechnology and GlaxoSmithKline (GSK) are moving ahead with regulatory submission of their COVID-19 monoclonal antibody (mAb), VIR-7831, after a...

U.S. purchases another 100K doses of Lilly COVID-19 antibodies
The U.S. government is purchasing a minimum of 100,000 doses of Eli Lilly's bamlanivimab 700 mg and etesevimab 1,400 mg together, which are neutralizing...

GSK, Vir partner on infectious diseases therapies
GlaskoSmithKline (GSK) and Vir Biotechnology have signed a deal to research and develop new therapies for influenza and other respiratory viruses.